Bank Of Hawaii Q3 2022 vs. Q4 2022 13F Holdings Comparison

Investment funds are an essential tool for investors looking to diversify their portfolios while minimizing the risk associated with market volatility. As such, 13F filings provide valuable insights into the changes made by various prominent institutions, reflecting a profound impact on the markets' movement. In this article, we explore the detailed comparison of Bank of Hawaii's Q3 2022 holdings and Q4 2022 holdings as per the 13F filings.

During this period, Bank of Hawaii made notable gains in the number of shares held in various companies, particularly Vanguard Group, which accounts for the majority of its portfolio. The following are some of the significant gains and losses made over the third and fourth quarters of 2022.

Vanguard

Bank of Hawaii recorded excellent gains in shares held for various Vanguard Groups, which represent the highest percentage of its portfolio. VEA, the Vanguard FTSE Developed Markets ETF, increased by 56% to 3.3 million shares, with the value of shares rising by 39.1% to $140,694,000. Similarly, VTI and VTV, the Vanguard Total Stock Market ETF and Vanguard Value ETF respectively, experienced rises in shares held of 1.6% and 5.01%, but the values of shares were impacted positively. The changes in shares and values of these ETFs indicate that Bank of Hawaii is bullish on the market in general and the Vanguard Group in particular.

Microsoft Corp

Bank of Hawaii added 1.3% more shares of Microsoft Corp in Q4 as compared to Q3, holding 139,178 shares valued at $33,377,000. Microsoft has been consistently appreciated, conversely deriving significant returns to investors. Its move to focus more on cloud computing services and business software resulted in an 85.5% stock appreciation over the past three years, reflecting Bank of Hawaii's confidence in the brand.

Pfizer Inc.

Bank of Hawaii minimized its holdings in Pfizer Inc., an American multinational pharmaceutical corporation, by 2.3% over Q3 2022, holding only 143,125 shares valued at $7,333,000 in Q4 2022. This move shows Bank of Hawaii's lack of confidence in the pharmaceutical giant despite its ongoing commitment to producing and distributing COVID vaccine boosters worldwide.

The bottom line

Overall, Bank of Hawaii's 13F filings show a bright outlook for the company, reflecting a positive sentiment towards some of the market's biggest players. Regardless of which way the market moves, Bank of Hawaii is well-positioned with diverse holdings, optimizing their profits on long-term growth strategies. As always, past performance is not indicative of future results, and investors must exercise due diligence before making any investment decisions.